• Vaso-occlusive crises in patients with sickle cell disease.

Contraindicated in:

• None reported.

Use Cautiously in:

• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Children <16 yr (safety and effectiveness not established).

Derm: pruritus.

GI: abdominal pain, nausea, diarrhea, vomiting.

Local: infusion-site reaction.

MS: arthralgia, back pain, myalgia.

Misc: fever, infusion-related reactions.

Drug-Drug:

• None reported.

• Solution for injection: 10 mg/mL;

• IV (Adults and Children ≥16 yr): 5 mg/kg initially, then in 2 wk, and then every 4 wk thereafter.

Adakveo

• Binds to P-selectin on the surface of the activated endothelium and platelets to prevent their interaction with endothelial cells, platelets, red blood cells, and white blood cells.

• Reduction in frequency of vaso-occlusive crises.

Therapeutic Classification: n/a

Pharmacologic Classification: monoclonal antibodies

Absorption: IV administration results in complete bioavailability.

Distribution: Minimally distributed to extravascular tissues.

Metabolism/Excretion: Metabolized by catabolic pathways into smaller peptides; excretion pathway unknown.

Half-life: 10.6 days.

(plasma concentrations)

• Explain the purpose of crizanlizumab to patient. Do not stop receiving crizanlizumab without consulting health care professional. If an appointment is missed, contact health care professional as soon as possible to reschedule. Advise patient to read Medication Guide before starting and periodically during therapy in case of changes.
• Advise patient to notify health care professional if signs and symptoms of infusion reactions (fever, chills or shivering, nausea, vomiting, tiredness, dizziness, sweating, hives, itching, shortness of breath, wheezing) occur.
• Instruct patient to inform health care professional of crizanlizumab therapy before blood tests due to potential interference with laboratory tests used to measure platelet counts.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Rep: May cause fetal harm. Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

KRIZ-an-LIZ-ue-mab

NDC Code^*

• 0078- Novartis Pharmaceuticals Corporation
  • 0078-0883- ADAKVEO
    • 0078-0883-61- 10 mL in 1 VIAL, GLASS (0078-0883-61)